Moreover, the mechanism of action of tirzepatide, a dual GIP and GLP-1 RA recently approved for use in patients with T2DM, indicates its high potential in the treatment of pasireotide-associated hyperglycemia. This evidence concerns the gene GIP and type 2 diabetes mellitus.